PRGR_CANFA NR3C3 ELISA tesk kit

Price:

1 011.15 €

Known as:: PRGR_CANFA NR3C3 Enzyme-linked immunosorbent assay test tesk reagent
Catalog number:: gen16336
Product Quantity:: 1
Category:: Peptides
Supplier:: Other suppliers
Gene target:: PRGR_CANFA NR3C3 ELISA tesk kit

Related genes to: PRGR_CANFA NR3C3 ELISA tesk kit

Gene:: PGR ^{NIH gene}
Name:: progesterone receptor
Previous symbol:: -
Synonyms:: PR, NR3C3
Chromosome:: 11q22.1
Locus Type:: gene with protein product
Date approved:: 2001-06-22
Date modifiied:: 2018-07-11

Related products to: PRGR_CANFA NR3C3 ELISA tesk kit

Human ELC ELISA KIT 96 TEST OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size OxiSelect Methylglyoxal (MG) Competitive ELISA Kit OxiSelect Methylglyoxal (MG) Competitive ELISA Kit OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit

Related articles to: PRGR_CANFA NR3C3 ELISA tesk kit

Zebrafish xenografts reveal line-specific patterns of growth, survival, and metastases in canine mammary cell lines: CMT-U27, CMT-U131, and CMT-U229.
Canine mammary tumours (CMTs) are the most common malignancies in female dogs and represent a valuable comparative model for human breast cancer. This study aimed to characterise the molecular and functional profiles of three CMT cell lines: CMT-U27, CMT-U131 and CMT-U229, using a zebrafish xenograft model. Gene ex-pression analysis targeted proliferation markers (MKI67, CCNB1, MYBL2, BIRC5, AURKA), receptor signalling (ESR1, PGR, AR, ERBB2, GRB7, EGFR), apoptosis and survival (BCL2, BAG1), and angiogenesis (VEGFA). Zebrafish larvae were xenotransplanted with tumour cells into either the Perivitelline Space or the Duct of Cuvier to assess larval survival and metastatic spread. The CMT-U27 displayed the most aggressive phenotype, with high expression of proliferation-associated genes and the highest metastatic frequency (60%). CMT-U229 exhibited moderate proliferation, accompanied by overexpression of VEGFA. In contrast, CMT-U131 exhibited lower proliferation, correlating with reduced survival in circulation and limited metastasis (<20%). This study provides the first comprehensive molecular characterisation of CMT cell lines in a zebrafish xenograft model. The findings underline the distinct biological profiles of these lines and demonstrate the utility of this platform for testing targeted therapies in veterinary oncology with translational relevance to human breast cancer. - Source: PubMed
Publication date: 2026/05/12
Chmielewska-Krzesińska MałgorzataDybalska-Szczepanek Joanna
Development of a pyrogallol-formaldehyde resin column for one-step pre-purification of Ge/Ga generator eluates: Enhanced [Ga]Ga-DOTA-TATE radiolabeling yield by selective removal of tetravalent cationic impurities.
A pyrogallol-formaldehyde resin (PGR) column was developed for one-step pre-purification of Ge/Ga generator eluates. The resin selectively adsorbs tetravalent cations (Ge, Sn, Ti) with efficiencies of 81.8%, 42.4%, and 29.8% in standards, reducing Sn and Ti to undetectable levels in generator eluates. Formaldehyde leaching was negligible, and cell viability remained 98% ± 1.7%, confirming biocompatibility. Ge breakthrough decreased >20-fold (0.0008 ± 0.0001% to 0.00003 ± 0.00002%). Manual [Ga]Ga-DOTA-TATE labeling yield increased from 58.9 ± 6% to 75.9 ± 1.8% (n = 10). The column is reusable for ≥10 runs. PGR enables high-purity, high-yield Ga radiopharmaceutical synthesis without additional processing time, resolving pH-dependent tetravalent cation interference via colloid mitigation. - Source: PubMed
Publication date: 2026/05/30
Ebrahimi FatemehGhiamaty ZahraRoustaei SaraMokhtari Kheirabadi AminBeiki DavoodRezanejad Bardeji ZahirNikkholgh BabakKaviani HaniehAkhlaghi Mehdi
The Use of Tomographs in Brazil's National Health System: Case Study on the Efficiency of the Public Network in Rio Grande do Norte.
The evaluation of health technologies is fundamental to the sustainability of the Brazilian National Health System (SUS), especially in highly complex and costly procedures such as computed tomography (CT). - Source: PubMed
Publication date: 2026/06/01
Barreto Tiago de Oliveirade Oliveira Júnior Elinaldo BernardoDos Santos Felipe Israel Joséde Lima Paiva Jordana CrislayneRodrigues Veras Nicolas Viniciusde Macedo Silva LorenaMacedo da Costa João MariaSantos de Aragão ÉrikaGóis Farias de Moura Santos Lima Thaísada Costa Barros CélioSilveira E Silva RafaelRocha de Andrade FernandoHolanda Cardoso PabloSantos Pinheiro AndréaMedeiros Machado GuilhermeMiranda Veloso Claudia MariaSimões Camara Leão LucianaDantas Coutinho Karilanyde Medeiros Valentim Ricardo Alexsandro
Preoperative onapristone-XR in postmenopausal women with progesterone receptor-positive (PgR+)/HER2-negative early breast cancer: SOLTI-1802 ONAWA trial results.
Onapristone, a type-1 antiprogestin, has been tested for advanced breast cancer (BC), but its activity in early-stage, hormone receptor-positive, HER2-negative BC has not been fully explored. The ONAWA trial (ClinicalTrials.gov ID: NCT04142892- Registered on January 6, 2021) was a single-arm study evaluating the preoperative effects of onapristone with extended-release formulation (ONA-XR) (50 mg BID for 21 days) in postmenopausal women with Progesterone Receptor-positive (PgR+)/HER2-negative early BC. No complete cell cycle arrest (CCCA) was achieved at day 21, however ONA-XR significantly suppressed tumor proliferation with a Ki-67 geometric mean change of -17.78% (CI95 -39.76% to 12.20%) particularly in tumors with baseline PgR≥90% (-46.21%; CI -63.02% to -21.76%). Immunohistochemistry showed suppression of phospho-Ser294-PgR and p-STAT3, indicating effects on proliferation and endocrine pathways. Treatment also induced a shift to a more endocrine-sensitive phenotype. Of the 10 patients, 60% experienced adverse events, including one grade 3 increase in gamma-glutamyltransferase. In conclusion, ONA-XR showed early tumor proliferation suppression, particularly in high PgR-expressing tumors, supporting its potential for further clinical evaluation. - Source: PubMed
Publication date: 2026/05/29
Bellet MeritxellFerrero-Cafiero Juan MBergamino Sirvén MilanaFalato ClaudetteGonzález XavierAmillano KepaChic NuriaMorales SerafinGasol AriadnaNuciforo PaoloVillacampa GuillermoVillagrasa PatriciaDiep Caroline HSeelig DavisLange CarolD'Assoro AntonioPrat AleixPascual TomásSaura Cristina
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study.
In hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC), the prognostic significance of estrogen receptor (ER), progesterone receptor (PgR), and HER2 immunohistochemical expression levels in patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) remains unclear. The CYCLHER study was designed to evaluate treatment outcomes and identify biologically driven prognostic factors. - Source: PubMed
Publication date: 2026/05/19
Pontolillo LetiziaMunzone ElisabettaVigneri PaoloPistelli MircoPalazzo AntonellaLa Verde NiclaMazzotta MarcoParis IdaAlesini DanieleSantini DanieleCannita KatiaOrlandi ArmandoMagnolfi EmanuelaGiacinti LauraRaffaele MimmaCarbognin LuisaSantoro AngelaRossi AlessandroArcuri GiorgiaSangalli ClaudiaGarrone OrnellaMulè AntonioValenza CarmineBerardi RossanaTortora GiampaoloBria EmilioCurigliano GiuseppeGiannarelli DianaFabi Alessandra

PRGR_CANFA NR3C3 ELISA tesk kit

Related genes to: PRGR_CANFA NR3C3 ELISA tesk kit

Related products to: PRGR_CANFA NR3C3 ELISA tesk kit

Related articles to: PRGR_CANFA NR3C3 ELISA tesk kit

Zebrafish xenografts reveal line-specific patterns of growth, survival, and metastases in canine mammary cell lines: CMT-U27, CMT-U131, and CMT-U229.

Development of a pyrogallol-formaldehyde resin column for one-step pre-purification of Ge/Ga generator eluates: Enhanced [Ga]Ga-DOTA-TATE radiolabeling yield by selective removal of tetravalent cationic impurities.

The Use of Tomographs in Brazil's National Health System: Case Study on the Efficiency of the Public Network in Rio Grande do Norte.

Preoperative onapristone-XR in postmenopausal women with progesterone receptor-positive (PgR+)/HER2-negative early breast cancer: SOLTI-1802 ONAWA trial results.

Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study.